CelLBxHealth has completed an oversubscribed US$10.9 million fundraise

Dezember 2025 — CelLBxHealth has completed an oversubscribed US$10.9 million fundraise comprising a placing, subscription and retail offer.

CelLBxHealth is a specialist diagnostics company. Its proprietary Parsortix® technology can capture and harvest very rare cells, including circulating tumor cells (CTCs), from a blood sample. Parsortix has received FDA clearance for clinical use to guide precision cancer care.

Unsere Rolle bei der Transaktion

Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised and supported CelLBxHealth in its fundraise. The transaction was particularly challenging given the company’s previously disclosed funding runway into the first quarter of 2026, as well as the rapid onboarding of a new management team. The new team, led by Jan Groen and Peter Collins, was delighted by the level of support from existing holders alongside substantial interest from new investors. Notably, the company raised more than twice its market capitalization, with investor demand ultimately scaled back. The strength of participation reflects investor support for the company’s strategy, its new leadership and confidence in its core technology.

DIENSTLEISTUNG

Beschaffung von Kapital

PARTEIEN

«We were delighted to see strong support in the fundraise from both existing shareholders and non-holders. This heavily oversubscribed funding gives us the much-needed capital to pursue our revised business strategy as we focus on the substantial market opportunity for the Parsortix platform. It was a pleasure working with Oaklins Cavendish, whose support helped bring all sides of the business together to deliver a successful fundraise despite very challenging circumstances. We look forward to significant commercial progress in 2026 and beyond.»

Peter Collins

Interim CEO, CelLBxHealth

Sprechen Sie mit dem Deal Team

Geoff Nash

Director

London, Grossbritannien
Oaklins Cavendish

Kurzprofil Kontakt aufnehmen

Transaktionen

OEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value

Private Equity | TMT

OEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value

OEP Danzig BidCo S.p.A. has completed a mandatory tender offer for the shares of Digital Value S.p.A.

Mehr erfahren

Verdane has completed the acquisition of Augmentum Fintech

Finanzdienstleistungen

Verdane has completed the acquisition of Augmentum Fintech

Following the acceptance of its offer and subsequent shareholder approval, Augmentum Fintech plc has been acquired by Verdane Advisors AS.

Mehr erfahren

UKAT Group has acquired Bayberry Limited

Private Equity | Gesundheitswesen

UKAT Group has acquired Bayberry Limited

UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.

Mehr erfahren